Adults with glomerular disease have a more than twofold risk of cardiovascular (CV) events compared with the general population, with the risk varying by type of glomerular disease, according to a retrospective study presented at ASN Kidney Week 2020.
The REDUCE-IT* RENAL study, a substudy of the REDUCE-IT trial, reflected the consistent benefit of icosapent ethyl (IPE) in statin-treated patients with established** cardiovascular disease (CVD) or diabetes, regardless of eGFR*** status.
Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.
The administration of upacicalcet – a novel, small-molecule calcimimetic agent in late-stage development in Japan – led to a significant reduction in serum intact parathyroid hormone (iPTH) level without increasing upper gastrointestinal (GI) symptoms in patients who have secondary hyperparathyroidism following haemodialysis, according to a phase III trial presented at ASN Kidney Week 2020.
Adding nutritional supplements, particularly protein, to diet of patients undergoing haemodialysis does not give an edge in survival compared with standard nutritional supplements, according to the HELPS-HD* study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.